These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 645511)
1. Role of prostaglandin E1 and E2 in the management of neonatal heart disease. Olley PM; Coceani F; Rowe RD Adv Prostaglandin Thromboxane Res; 1978; 4():345-53. PubMed ID: 645511 [No Abstract] [Full Text] [Related]
2. Prostaglandins and the management of congenital heart disease. Taylor WJ; Alpert BS Am Fam Physician; 1982 Dec; 26(6):127-32. PubMed ID: 6890758 [TBL] [Abstract][Full Text] [Related]
3. Effects of prostaglandins and blockers of prostaglandin synthesis on the ductus arteriosus: animal and human studies. Heymann MA; Rudolph AM Adv Prostaglandin Thromboxane Res; 1978; 4():363-72. PubMed ID: 645512 [No Abstract] [Full Text] [Related]
5. Prostaglandin E1 infusion: successful initial treatment. Linday L; Levin AR; Reitman M; Engle MA N Y State J Med; 1981 Feb; 81(2):218-21. PubMed ID: 6936640 [No Abstract] [Full Text] [Related]
6. [Value of prostaglandin E1 in cardiac malformations in the newborn infant]. Sassolas F; Bozio A; Andre M; Jocteur-Monrozier D; Champsaur G; Normand J Pediatrie; 1984 Jun; 39(4):245-52. PubMed ID: 6504667 [TBL] [Abstract][Full Text] [Related]
7. Use of prostaglandin E1 for maintaining the patency of the ductus arteriosus. Noah ML Adv Prostaglandin Thromboxane Res; 1978; 4():355-62. PubMed ID: 347914 [TBL] [Abstract][Full Text] [Related]
8. Comments on the pharmacologic manipulation of the ductus arteriosus in newborns. Rowe RD Adv Prostaglandin Thromboxane Res; 1978; 4():383-5. PubMed ID: 645513 [No Abstract] [Full Text] [Related]
10. [Prostaglandin E1 therapy in infants with cyanotic congenital heart malformations: hemodynamic and angiographic findings (author's transl)]. Schumacher G; Mocellin R; Schöber JG; Kellner M; Bühlmeyer K Klin Padiatr; 1978 Sep; 190(5):465-73. PubMed ID: 568198 [TBL] [Abstract][Full Text] [Related]
11. Proceedings: Emergency treatment of certain cyanotic heart defects with prostaglandin E2. Olley PM; Coceani F Br Heart J; 1976 Aug; 38(8):877. PubMed ID: 973917 [No Abstract] [Full Text] [Related]
12. Prostaglandin and damage to ductus arteriosus. Moulaert AJ; Gittenberger AC; Harinck E Lancet; 1977 Mar; 1(8013):703-4. PubMed ID: 66503 [No Abstract] [Full Text] [Related]
13. [Effects of prostaglandin in heart abnormalities with needed patency of the arterial canal (clinical and histological study)]. Moulaert A; Gittenberger-De Groot A; Harinck E Arch Fr Pediatr; 1978; 35(7):717-25. PubMed ID: 736728 [TBL] [Abstract][Full Text] [Related]
15. [Skeletal side effects of treatment with prostaglandin E1]. Persigehl M; Hövels-Gürich H; von Bernuth G Rofo; 1984 Oct; 141(4):427-30. PubMed ID: 6436918 [TBL] [Abstract][Full Text] [Related]
16. Prostaglandin treatment of newborns with ductal-dependent congenital heart disease. Linday LA; Engle MA Pediatr Ann; 1981 Apr; 10(4):29-38. PubMed ID: 7232040 [No Abstract] [Full Text] [Related]
17. Use of prostaglandins in cardiopulmonary diseases of the newborn. Olley PM; Coceani F Semin Perinatol; 1980 Apr; 4(2):135-41. PubMed ID: 6990504 [No Abstract] [Full Text] [Related]
18. [Long-term treatment using prostaglandin E2 in congenital heart defects with the pulmonary circulation being supplied by a patent ductus arteriosus]. Hruda J; Samánek M; First T; Vorísková M; Skovránek J Cesk Pediatr; 1985 May; 40(5):257-62. PubMed ID: 3860302 [No Abstract] [Full Text] [Related]